Trial Condition(s):
Exit interviews to assess impact of infusion frequency in Hemophilia A
19144
Not Available
Not Available
This study is to generate qualitative data to evaluate the impact of frequency of FVIII infusions on patients’ satisfaction with treatment and their quality of life.
- Patient is enrolled in the BAY94-9027 extension studies or is within 3 months of having completed participation in the BAY94-9027 extension studies; - Patient allocated to Arm 2, Arm 3 or Arm 4 of BAY94-9027 extension studies. -- Arm 2 Prophylaxis treatment of BAY94-9027; 2 infusions per week during the extension study --Arm 3 Prophylaxis treatment of BAY94-9027; infusion every 5 days during the extension study --Arm 4 Prophylaxis treatment of BAY94-9027; every 7 days during the extension study - Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study; - Patient must be willing and able to participate in a telephone interview lasting up to 30 minutes; - Patient must have sufficient cognitive and linguistic capacities to allow them to actively participate in an interview lasting 30 minutes.
- Patient is part of Arm 1: On-demand treatment of BAY94-9027 at individual dose and number of infusions based upon location and severity of bleeds; - Patient is unlikely to comply with the study protocol (e.g. uncooperative attitude) or unlikely to complete the study for any reason in the opinion of the recruiter; - Patient has great difficulty hearing or reading; - Patient has any significant comorbid condition (including uncontrolled psychiatric conditions) that might limit or interfere with their ability to talk about their Hemophilia A and participate in the study; - Patient has severe neurological or cognitive deficits that might affect their ability to participate in an interview.
Locations | Status | |
---|---|---|
Locations Cleveland Cleveland, United States, 110605 | Status Completed | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Exit interviews to assess impact of infusion frequency in Hemophilia A
Trial Type:
Observational
Intervention Type:
Biological/Vaccine
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
3
Not Available